← FDA DRUG APPROVALS

FDA NDA · NDA017938

MOBAN

Sponsor: ENDO PHARMS

APPLICATION
NDA017938
TYPE
NDA
ORIGINAL APPROVAL
1979-12-28
LATEST ACTION
2002-01-15
ROUTE
ORAL
DOSAGE FORM
CONCENTRATE
MARKETING STATUS
Discontinued

Products

MOBANDiscontinued
MOLINDONE HYDROCHLORIDE 20MG/ML · CONCENTRATE · ORAL

Approval history

2002-01-15Manufacturing (CMC) · Supplement 23 · standardAP
2001-05-22Labeling · Supplement 22 · standardLetterAP
1998-08-21Manufacturing (CMC) · Supplement 21 · standardAP
1996-04-25Manufacturing (CMC) · Supplement 19 · standardAP
1995-08-28Manufacturing (CMC) · Supplement 18 · standardAP
1995-08-28Manufacturing (CMC) · Supplement 16 · standardAP
1995-08-28Manufacturing (CMC) · Supplement 17 · standardAP
1984-06-21Manufacturing (CMC) · Supplement 9 · standardAP
1982-11-19Labeling · Supplement 7 · standardAP
1981-11-16Manufacturing (CMC) · Supplement 4 · standardAP
1981-03-24Labeling · Supplement 3 · standardAP
1981-01-05Labeling · Supplement 2 · standardAP
1979-12-28Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →